Updates are available Correction dated 2025-01-16
Click to view Correction: https://doi.org/10.1038/s41591-025-03503-2
-
Authors
Jamialahmadi, Oveis https://orcid.org/0000-0001-7139-4738
De Vincentis, Antonio
Tavaglione, Federica https://orcid.org/0000-0002-1720-4355
Malvestiti, Francesco https://orcid.org/0000-0002-2430-5883
Li-Gao, Ruifang
Mancina, Rosellina M. https://orcid.org/0000-0002-1126-3071
Alvarez, Marcus https://orcid.org/0000-0002-6369-5028
Gelev, Kyla
Maurotti, Samantha
Vespasiani-Gentilucci, Umberto
Rosendaal, Frits Richard https://orcid.org/0000-0003-2558-7496
Kozlitina, Julia https://orcid.org/0000-0001-7720-2290
Pajukanta, Päivi https://orcid.org/0000-0002-6423-8056
Pattou, François
Valenti, Luca https://orcid.org/0000-0001-8909-0345
Romeo, Stefano https://orcid.org/0000-0001-9168-4898
- License Information
-
More Information
Article History
Received: 19 January 2024
Accepted: 30 August 2024
First Online: 9 December 2024
Change Date: 16 January 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-025-03503-2
Competing interests
: S.R. has been consulting for AstraZeneca, GSK, Celgene Corporation, Ribo-cure AB and Pfizer in the last 5 years and received a research grant from AstraZeneca. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the paper or in the decision to publish the results. L.V. has received speaking fees from MSD, Gilead, AlfaSigma and AbbVie, served as a consultant for Gilead, Pfizer, AstraZeneca, Novo Nordisk, Intercept, Diatech Pharmacogenetics, Ionis Pharmaceuticals, Boehringer Ingelheim and Resalis Therapeutics, and received unrestricted research grants from Gilead. R.L.G. is a part-time contractor for Metabolon. O.J. is a part-time consultant to Ribo-cure AB. The other authors declare no competing interests.
